3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
3
Diabetes Mellitus
2
Vomiting
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Prostatic Neoplasms
1
Premature Birth
1
Pre-Eclampsia
1
Polycystic Ovary Syndrome
1
Parathyroid Neoplasms
1
Neoplasms
1
Medulloblastoma
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Hairy Cell
1
Leukemia, B-Cell
1
Leiomyosarcoma
1
Hyperparathyroidism, Primary
1
Hot Flashes
1
HER2 IHC3+ Advanced Colorectal Cancer
1
Erectile Dysfunction
1
Cognitive Dysfunction
1
Carcinoma, Renal Cell
1
Interventions
Rituximab
49
Cyclophosphamide
28
venetoclax
24
Bendamustine Hydrochloride
24
obinutuzumab
22
ibrutinib
21
Chlorambucil
20
fludarabine
16
fludarabine phosphate
15
idelalisib
13
acalabrutinib
11
pirtobrutinib
7
ofatumumab
7
zanubrutinib
5
Vincristine
5
Peripheral Blood Stem Cell Transplantation
5
Mycophenolic Acid
5
Cyclosporine
5
Radiotherapy
4
Prednisone
4
Doxorubicin
4
duvelisib
3
Whole-Body Irradiation
3
Specimen Handling
3
Methotrexate
3
Lenalidomide
3
Filgrastim
3
Epoetin Alfa
3
Cyclosporins
3
Biopsy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Leukemia, Lymphocytic, Chronic, B-Cell
×
Tablets
×
Clear all
NCT00748189
2019-06-25
COMPLEMENT 1
Novartis
Phase 3
Terminated
447 enrolled
32 charts